Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Biodesix, Inc. Common Stock

$16.03

+0.81 (+5.32%)

F 8Pipeline Score Tools & Services · Commercial
Market Cap
129.44 M
EPS
-4.73
P/E Ratio
-2.77 $
Value Trade
326.72 K
SEC Financials
Q1 2026

  • Dilution Risk

    60%

  • Revenue

    25.55 M

  • R&D Expenses

    3.29 M

  • Operating CF

    -10.17 M

  • Total Assets

    94.64 M

  • Total Liabilities

    85.50 M

  • Equity

    9.13 M

  • D/E Ratio

    12,345

%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Caution

  • Cash Position

    25.57 M

  • Monthly Burn

    3.39 M

  • Runway

    6 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 4, 2026
Overview
Volume
21.32 K
52 Week Range
3.44 - 20.21
% held by Insiders
55.01 %
% held by Institutions
37.68 %
Enterprise Value
183.21 M
Total Shares
10.06 M
Short %
2.28 %
Float Shares
4.95 M
Company Description
HQ: 919 WEST DILLON ROAD, LOUISVIL...
Employees:334
https://www.biodesix.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
F8
Pipeline Score
-
Pipeline Value
Valuation Signal
0
Drugs Scored
—
rNPV / MCap
Top 6%
Micro Cap
(rank 852 of 905)
Percentile Rank
Biodesix, Inc. Common Stock has significant pipeline risk (8/100).
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in BDSX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biodesix, Inc. Common Stock (BDSX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
BDSX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BDSX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BDSX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
BDSX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
BDSX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-BDSX
May 11, 2026
BDSXConferences/Events

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

Biodesix, Inc. announced that it will present real-world clinical and economic data related to its Nodify Lung testing at the ATS Annual Meeting from May 15-20, 2026. The presentations aim to demonstrate the value of blood-based testing in lung cancer detection and management. CEO Scott Hutton emphasized the importance of these tests in enhancing patient care and outcomes.

Read more →
-BDSX
Apr 20, 2026
BDSXConferences/Events

Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026

Biodesix, Inc. announced its financial results for Q1 2026 will be released on May 4, 2026. A conference call and webcast will follow to discuss these results and provide a business update. The company emphasizes its commitment to improving clinical care through its diagnostic solutions.

Read more →
-BDSX
Mar 20, 2026
BDSXPhases

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

Biodesix announced the publication of the largest clinical validation study for lung nodule biomarkers, supporting the Nodify CDT test's role in early lung cancer detection. The study demonstrated high specificity and consistent performance across various clinical settings, addressing a critical need in managing lung nodules. The findings are expected to enhance clinical decision-making and patient outcomes.

Read more →
-BDSX
Feb 24, 2026
BDSXConferences/Events

Biodesix to Participate in Upcoming Investor Conferences

Biodesix, Inc. (Nasdaq: BDSX) has announced its participation in two upcoming investor conferences, including TD Cowen's 46th Annual Health Care Conference and Barclays 28th Annual Global Healthcare Conference. The management team will engage in fireside chats, which will be available for live streaming and replay on the company's website. This initiative highlights Biodesix's commitment to enhancing investor relations and promoting its diagnostic solutions.

Read more →
-BDSX
Feb 24, 2026
BDSXConferences/Events

Biodesix to Participate in Upcoming March 2026 Investor Conferences

Biodesix, Inc. has announced its participation in two upcoming investor conferences in March 2026. The management team will engage in fireside chats at the TD Cowen's 46th Annual Health Care Conference in Boston and the Barclays 28th Annual Global Healthcare Conference in Miami. These events aim to enhance investor relations and showcase the company's diagnostic solutions.

Read more →
-BDSX
Feb 12, 2026
BDSXGeneral

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Biodesix, Inc. has announced the release of its financial results for Q4 and the full year of 2025, scheduled for February 26, 2026. The company will host a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a business update. Interested parties can register for the webcast and participate in a Q&A session.

Read more →
Competitive Position
How BDSX ranks across every disease it competes in
Competitive Position is a premium feature
See how BDSX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial